Second-line biologic therapy optimization in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis

Seminars in Arthritis and Rheumatism

Volumn 47, Issue 2, 2017, Pages 183-192

  Cantini, Fabrizio ^a   Niccoli, Laura ^a   Nannini, Carlotta ^a   Cassarà, Emanuele ^a   Kaloudi, Olga ^a   Giulio Favalli, Ennio ^b   Becciolini, Andrea ^b   Benucci, Maurizio ^c   Gobbi, Francesca Li ^c   Guiducci, Serena ^d   Foti, Rosario ^e   Mosca, Marta ^f   Goletti, Delia ^g  

^a HOSPITAL OF PRATO   (Italy)

^b ISTITUTO ORTOPEDICO GAETANO PINI   (Italy)

^c Hospital S Giovanni di Dio   (Italy)

^d UNIVERSITY OF FLORENCE   (Italy)

^e UNIVERSITY OF CATANIA   (Italy)

^f UNIVERSITY OF PISA   (Italy)

^g NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

Author keywords

Anti TNF; Psoriatic arthritis; Rheumatoid arthritis; Second line biologics; Spondyloarthritis; Switching

Indexed keywords

ABATACEPT; ADALIMUMAB; ANTIRHEUMATIC AGENT; CERTOLIZUMAB PEGOL; ETANERCEPT; GOLIMUMAB; INFLIXIMAB; PLACEBO; RITUXIMAB; SECUKINUMAB; TOCILIZUMAB; TUMOR NECROSIS FACTOR ANTIBODY; USTEKINUMAB; BIOLOGICAL PRODUCT; MONOCLONAL ANTIBODY;

ANKYLOSING SPONDYLITIS; CANCER RISK; CARDIOVASCULAR RISK; DACTYLITIS; DISEASE SEVERITY; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG INDICATION; DRUG RESPONSE; ENTHESITIS; HUMAN; INFECTION RISK; MONOTHERAPY; PATIENT PREFERENCE; PRIORITY JOURNAL; PROCESS OPTIMIZATION; PSORIATIC ARTHRITIS; REVIEW; RHEUMATOID ARTHRITIS; SPONDYLARTHRITIS; SYSTEMATIC REVIEW; TREATMENT FAILURE; RETREATMENT;

ADALIMUMAB; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, PSORIATIC; ARTHRITIS, RHEUMATOID; BIOLOGICAL PRODUCTS; ETANERCEPT; HUMANS; RETREATMENT; SPONDYLITIS, ANKYLOSING;

EID: 85017457055     PISSN: 00490172     EISSN: 1532866X     Source Type: Journal    
DOI: 10.1016/j.semarthrit.2017.03.008     Document Type: Review

References (116)

1. Cantini, F., Niccoli, L., Nannini, C., Cassarà, E., Kaloudi, O., Favalli, E., et al. Tailored first-line biologic therapy in patients with rheumatoid arthritis, spondyloarthritis, and psoriatic arthritis. Semin Arthritis Rheum 45 (2016), 519–532.
2. Souto, A., Maneiro, J.R., Gómez-Reino, J.J., Rate of discontinuation and drug survival of biologic therapies in rheumatoid arthritis: a systematic review and meta-analysis of drug registries and health care databases. Rheumatology (Oxford) 55 (2016), 523–534.
3. Glintborg, B., Østergaard, M., Dreyer, L., Krogh, N.S., Tarp, U., Hansen, M.S., et al. Treatment response, drug survival, and predictors thereof in 764 patients with psoriatic arthritis treated with anti-tumor necrosis factor α therapy: results from the nationwide Danish DANBIO registry. Arthritis Rheum 63 (2011), 382–390.
4. Glintborg, B., Østergaard, M., Krogh, N.S., Tarp, U., Manilo, N., Loft, A.G., et al. Clinical response, drug survival and predictors thereof in 432 ankylosing spondylitis patients after switching tumour necrosis factor α inhibitor therapy: results from the Danish nationwide DANBIO registry. Ann Rheum Dis 72 (2013), 1149–1155.
5. Fafá, B.P., Louzada-Junior, P., Titton, D.C., Zandonade, E., Ranza, R., Laurindo, I., et al. Drug survival and causes of discontinuation of the first anti-TNF in ankylosing spondylitis compared with rheumatoid arthritis: analysis from BIOBADABRASIL. Clin Rheumatol 34 (2015), 921–927.
6. Biggioggero, M., Favalli, E.G., Ten-year drug survival of anti-TNF agents in the treatment of inflammatory arthritides. Drug Dev Res 75:Suppl. 1 (2014), S38–S41.
7. Keystone, E.C., Kavanaugh, A., Sharp, J.T., Tannenbaum, H., Hua, Y., Teoh, L.S., et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum 50 (2004), 1400–1411.
8. Weinblatt, M.E., Kremer, J.M., Bankhurst, A.D., Bulpitt, K.J., Fleischmann, R.M., Fox, R.I., et al. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 340 (1999), 253–259.
9. Lipsky, P.E., van der Heijde, D.M., Clair, E.W.S., Furst, D.E., Breedveld, F.C., Kalden, J.R., et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 343 (2000), 1594–1602.
10. Smolen, J.S., Weinblatt, M.E., When patients with rheumatoid arthritis fail tumour necrosis factor inhibitors: what is the next step?. Ann Rheum Dis 67 (2008), 1497–1498.
11. Furst, D.E., Gaylis, N., Bray, V., Olech, E., Yocum, D., Ritter, J., et al. Open-label, pilot protocol of patients with rheumatoid arthritis who switch to infliximab after an incomplete response to etanercept: the opposite study. Ann Rheum Dis 66 (2007), 893–899.
12. Smolen, J.S., Kay, J., Doyle, M.K., Landewé, R., Matteson, E.L., Wollenhaupt, J., et al. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial. Lancet 374 (2009), 210–221.
13. Smolen, J.S., Kay, J., Doyle, M., Landewé, R., Matteson, E.L., Gaylis, N., et al. Golimumab in patients with active rheumatoid arthritis after treatment with tumor necrosis factor α inhibitors: findings with up to five years of treatment in the multicenter, randomized, double-blind, placebo-controlled, phase 3 GO-AFTER study. Arthritis Res Ther, 17, 2015, 14.
14. Weinblatt, M.E., Fleischmann, R., van Vollenhoven, R.F., Emery, P., Huizinga, T.W., Cutolo, M., et al. Twenty-eight-week results from the REALISTIC phase IIIb randomized trial: efficacy, safety and predictability of response to certolizumab pegol in a diverse rheumatoid arthritis population. Arthritis Res Ther, 17, 2015, 325.
15. Smolen, J.S., Burmester, G.R., Combe, B., Curtis, J.R., Hall, S., Haraoui, B., et al. Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXXELERATE study. Lancet 388 (2016), 2763–2774.
16. Gomez-Reino, J.J., Carmona, L., BIOBADASER Group, Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year period. Arthritis Res Ther, 8, 2006, R29.
17. Caporali, R., Sarzi-Puttini, P., Atzeni, F., Gorla, R., Filippini, M., Marchesoni, A., et al. Switching TNF-alpha antagonists in rheumatoid arthritis: the experience of the LORHEN registry. Autoimmun Rev 9 (2010), 465–469.
18. Iannone, F., Trotta, F., Montecucco, C., Montecucco, C., Giacomelli, R., Galeazzi, M., et al. Etanercept maintains the clinical benefit achieved by infliximab in patients with rheumatoid arthritis who discontinued infliximab because of side effects. Ann Rheum Dis 66 (2007), 249–252.
19. Virkki, L.M., Valleala, H., Takakubo, Y., Vuotila, J., Relas, H., Komulainen, R., et al. Outcomes of switching anti-TNF drugs in rheumatoid arthritis—a study based on observational data from the Finnish Register of Biological Treatment (ROB-FIN). Clin Rheumatol 30 (2011), 1447–1454.
20. Chatzidionysiou, K., Askling, J., Eriksson, J., Kristensen, L.E., van Vollenhoven, R.F., for the ARTIS group. Effectiveness of TNF inhibitor switch in RA: results from the national Swedish register. Ann Rheum Dis 74 (2014), 890–896.
21. Bombardieri, S., Ruiz, A.A., Fardellone, P., Geusens, P., McKenna, F., Unnebrink, K., et al. Effectiveness of adalimumab for rheumatoid arthritis in patients with a history of TNF-antagonist therapy in clinical practice. Rheumatology (Oxford) 46 (2007), 1191–1199.
22. Hyrich, K.L., Lunt, M., Watson, K.D., Symmons, D.P.M., Silman, A.J., British Society for Rheumatology Biologics Register, Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study. Arthritis Rheum 56 (2007), 13–20.
23. Solau-Gervais, E., Laxenaire, N., Cortet, B., Dubucquoi, S., Duquesnoy, B., Flipo, R.M., Lack of efficacy of a third tumour necrosis factor alpha antagonist after failure of a soluble receptor and a monoclonal antibody. Rheumatology (Oxford) 45 (2006), 1121–1124.
24. Karlsson, J.A., Kristensen, L.E., Kapetanovic, M.C., Gulfe, A., Saxne, T., Geborek, P., Treatment response to a second or third TNF-inhibitor in RA: results from the South Swedish Arthritis Treatment Group Register. Rheumatology (Oxford) 47 (2008), 507–513.
25. Hjardem, E., Østergaard, M., Pødenphant, J., Tarp, U., Andersen, L.S., Bing, J., et al. Do rheumatoid arthritis patients in clinical practice benefit from switching from infliximab to a second tumor necrosis factor alpha inhibitor?. Ann Rheum Dis 66 (2007), 1184–1189.
26. Rendas-Baum, R., Wallenstein, G.V., Koncz, T., Kosinski, M., Yang, M., Bradley, J., et al. Evaluating the efficacy of sequential biologic therapies for rheumatoid arthritis patients with an inadequate response to tumor necrosis factor-α inhibitors. Arthritis Res Ther, 13, 2011, R25.
27. Lequerré, T., Farran, É., Ménard, J.F., Kozyreff-Meurice, M., Vandhuick, T., Tharasse, C., et al. Switching from an anti-TNF monoclonal antibody to soluble TNF-receptor yields better results than vice versa: An observational retrospective study of 72 rheumatoid arthritis switchers. Joint Bone Spine 82 (2015), 330–337.
28. Smolen, J.S., Kay, J., Matteson, E.L., Landewé, R., Hsia, E.C., Xu, S., et al. Insights into the efficacy of golimumab plus methotrexate in patients with active rheumatoid arthritis who discontinued prior anti-tumour necrosis factor therapy: post-hoc analyses from the GO-AFTER study. Ann Rheum Dis 73 (2014), 1811–1818.
29. Emery, P., Keystone, E.C., Keystone, E.C., Tony, H.P., Tony, H.P., et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis 67 (2007), 1516–1523.
30. Genovese, M.C., Becker, J.-C., Schiff, M.H., Luggen, M., Sherrer, Y., Kremer, J., et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med 353 (2005), 1114–1123.
31. Cohen, S.B., Emery, P., Greenwald, M.W., Dougados, M., Furie, R.A., Genovese, M.C., et al. Rituximab for rheumatoid arthritis refractory to anti–tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 54 (2006), 2793–2806.
32. Keystone, E.C., Emery, P., Peterfy, C.G., Tak, P.P., Cohen, S., Genovese, M.C., et al. Rituximab inhibits structural joint damage in patients with rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitor therapies. Ann Rheum Dis 68 (2009), 216–221.
33. Gottenberg, J.E., Brocq, O., Perdriger, A., Lassoued, S., Berthelot, J.M., Wendling, D., et al. Non-TNF-targeted biologic vs a second anti-TNF drug to treat rheumatoid arthritis in patients with insufficient response to a first anti-TNF drug: a randomized clinical trial. J Am Med Assoc 316 (2016), 1172–1180.
34. Schoels, M., Aletaha, D., Smolen, J.S., Wong, J.B., Comparative effectiveness and safety of biological treatment options after tumour necrosis factor α inhibitor failure in rheumatoid arthritis: systematic review and indirect pairwise meta-analysis. Ann Rheum Dis 71 (2012), 1303–1308.
35. Moots, R.J., Naisbett-Groet, B., The efficacy of biologic agents in patients with rheumatoid arthritis and an inadequate response to tumour necrosis factor inhibitors: a systematic review. Rheumatology (Oxford) 51 (2012), 2252–2261.
36. Kekow, J., Mueller-Ladner, U., Schulze-Koops, H., Rituximab is more effective than second anti-TNF therapy in rheumatoid arthritis patients and previous TNFα blocker failure. Biologics 6 (2012), 191–199.
37. Finckh, A., Ciurea, A., Brulhart, L., Kyburz, D., Möller, B., Dehler, S., et al. B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agents. Arthritis Rheum 56 (2007), 1417–1423.
38. Chatzidionysiou, K., van Vollenhoven, R.F., Rituximab versus anti-TNF in patients who previously failed one TNF inhibitor in an observational cohort. Scand J Rehabil Med 42 (2013), 190–195.
39. Soliman, M.M., Hyrich, K.L., Lunt, M., Watson, K.D., Symmons, D.P.M., Ashcroft, D.M., et al. Rituximab or a second anti-tumor necrosis factor therapy for rheumatoid arthritis patients who have failed their first anti-tumor necrosis factor therapy? Comparative analysis from the British Society for Rheumatology Biologics Register. Arthritis Care Res 64 (2012), 1108–1115.
40. Blom, M., Kievit, W., Donders, A.R., Broeder den, A.A., Straten, V.H., Kuper, I., et al. Effectiveness of a third tumor necrosis factor-α-blocking agent compared with rituximab after failure of 2 TNF-blocking agents in rheumatoid arthritis. J Rheumatol 38 (2011), 2355–2361.
41. Emery, P., Gottenberg, J.E., Rubbert-Roth, A., Sarzi-Puttini, P., Choquette, D., Martínez-Taboada, V.M., et al. Rituximab versus an alternative TNF inhibitor in patients with rheumatoid arthritis who failed to respond to a single previous TNF inhibitor: SWITCH-RA, a global, observational, comparative effectiveness study. Ann Rheum Dis 74 (2016), 979–984.
42. Gomez-Reino, J.J., Maneiro, J.R., Ruiz, J., Roselló, R., Sanmarti, R., Romero, A.B., et al. Comparative effectiveness of switching to alternative tumour necrosis factor (TNF) antagonists versus switching to rituximab in patients with rheumatoid arthritis who failed previous TNF antagonists: the MIRAR Study. Ann Rheum Dis 71 (2012), 1861–1864.
43. Manders, S.H., Kievit, W., Adang, E., Brus, H.L., Moens, H.J., Hartkamp, A., et al. Cost-effectiveness of abatacept, rituximab, and TNFi treatment after previous failure with TNFi treatment in rheumatoid arthritis: a pragmatic multi-centre randomised trial. Arthritis Res Ther, 17, 2015, 134.
44. Favalli, E.G., Biggioggero, M., Marchesoni, A., Meroni, P.L., Survival on treatment with second-line biologic therapy: a cohort study comparing cycling and swap strategies. Rheumatology (Oxford) 53 (2014), 1664–1668.
45. Rotar, Z., Hočevar, A., Rebolj Kodre, A., Praprotnik, S., Tomšič, M., Slovenian Rheumatologists, Retention of the second-line biologic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis failing one tumor necrosis factor alpha inhibitor: data from the BioRx.si registry. Clin Rheumatol 34 (2015), 1787–1793.
46. Backhaus, M., Kaufmann, J., Richter, C., Wassenberg, S., Roske, A.E., Hellmann, P., Gaubitz, M., Comparison of tocilizumab and tumour necrosis factor inhibitors in rheumatoid arthritis: a retrospective analysis of 1603 patients managed in routine clinical practice. Clin Rheumatol 34 (2015), 673–681.
47. Harrold, L.R., Reed, G.W., Kremer, J.M., Curtis, J.R., Solomon, D.H., Hochberg, M.C., et al. The comparative effectiveness of abatacept versus anti-tumour necrosis factor switching for rheumatoid arthritis patients previously treated with an anti-tumour necrosis factor. Ann Rheum Dis 74 (2015), 430–436.
48. Hirabara, S., Takahashi, N., Fukaya, N., Miyake, H., Yabe, Y., Kaneko, A., et al. Clinical efficacy of abatacept, tocilizumab, and etanercept in Japanese rheumatoid arthritis patients with inadequate response to anti-TNF monoclonal antibodies. Clin Rheumatol 33 (2014), 1247–1254.
49. Kobayakawa, T., Kojima, T., Takahashi, N., Hayashi, M., Yabe, Y., Kaneko, A., et al. Drug retention rates of second biologic agents after switching from tumor necrosis factor inhibitors for rheumatoid arthritis in Japanese patients on low-dose methotrexate or without methotrexate. Mod Rheumatol 25 (2015), 251–256.
50. Das, S., Vital, E.M., Horton, S., Bryer, D., El-Sherbiny, Y., Rawstron, A.C., et al. Abatacept or tocilizumab after rituximab in rheumatoid arthritis? An exploratory study suggests non-response to rituximab is associated with persistently high IL-6 and better clinical response to IL-6 blocking therapy. Ann Rheum Dis 73 (2014), 909–912.
51. Pascart, T., Philippe, P., Drumez, E., Deprez, X., Cortet, B., Duhamel, A., et al. Comparative efficacy of tocilizumab, abatacept and rituximab after non-TNF inhibitor failure: results from a multicentre study. Int J Rheum Dis 19 (2016), 1093–1102.
52. Lubrano, E., Cantini, F., Costanzo, A., Girolomoni, G., Prignano, F., Olivieri, I., et al. Measuring psoriatic disease in clinical practice. An expert opinion position paper. Autoimmun Rev 14 (2015), 864–874.
53. Gossec, L., Coates, L.C., de Wit, M., Kavanaugh, A., Ramiro, S., Mease, P.J., et al. Management of psoriatic arthritis in 2016: a comparison of EULAR and GRAPPA recommendations. Nat Rev Rheumatol 12 (2016), 743–750.
54. Coates, L.C., Tillett, W., Chandler, D., Helliwell, P.S., Korendowych, E., Kyle, S., et al. The 2012 BSR and BHPR guideline for the treatment of psoriatic arthritis with biologics. Rheumatology (Oxford) 52 (2013), 1754–1757.
55. Braun, J., van den Berg, R., Baraliakos, X., Boehm, H., Burgos-Vargas, R., Collantes-Estevez, E., et al. 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 70 (2011), 896–904.
56. Acosta Felquer, M.L., Coates, L.C., Soriano, E.R., Ranza, R., Espinoza, L.R., et al. Drug therapies for peripheral joint disease in psoriatic arthritis: a systematic review. J Rheumatol 41 (2014), 2286–2289.
57. McInnes, I.B., Mease, P.J., Kirkham, B., Kavanaugh, A., Ritchlin, C.T., Rahman, P., et al. Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 386 (2015), 1137–1146.
58. Mease, P.J., McInnes, I.B., Kirkham, B., Kavanaugh, A., Rahman, P., van der Heijde, D., et al. Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis. N Engl J Med 373 (2015), 1329–1339.
59. Saad, A.A., Symmons, D.P., Noyce, P.R., Ashcroft, D.M., Risks and benefits of tumor necrosis factor-alpha inhibitors in the management of psoriatic arthritis: systematic review and metaanalysis of randomized controlled trials. J Rheumatol 35 (2008), 883–890.
60. Donahue, K.E., Jonas, D., Hansen, R.A., Roubey, R., Jonas, B., Lux, L.J., et al. Drug Therapy for Psoriatic Arthritis in Adults: Update of a 2007 Report [Internet]. 2012, Agency for Healthcare Research and Quality, Rockville (MD, USA) MID:22624163.
61. Fénix-Caballero, S., Alegre-del Rey, E.J., Castaño-Lara, R., Puigventós-Latorre, F., Borrero-Rubio, J.M., et al. Direct and indirect comparison of the efficacy and safety of adalimumab, etanercept, infliximab and golimumab in psoriatic arthritis. J Clin Pharm Ther 38 (2013), 286–293.
62. Lemos, L.L., de Oliveira Costa, J., Almeida, A.M., Junior, H.O., Barbosa, M.M., Kakehasi, A.M., et al. Treatment of psoriatic arthritis with anti-TNF agents: a systematic review and meta-analysis of efficacy, effectiveness and safety. Rheumatol Int 34 (2014), 1345–1360.
63. Mease, P.J., Ory, P., Sharp, J.T., Ritchlin, C.T., Van den Bosch, F., Wellborne, F., et al. Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT). Ann Rheum Dis 68 (2009), 702–709.
64. Mease, P.J., Kivitz, A.J., Burch, F.X., Siegel, E.L., Cohen, S.B., Ory, P., et al. Continued inhibition of radiographic progression in patients with psoriatic arthritis following 2 years of treatment with etanercept. J Rheumatol 33 (2006), 712–721.
65. Gladman, D.D., Bombardier, C., Thorne, C., Haraoui, B., Khraishi, M., Rahman, P., et al. Effectiveness and safety of etanercept in patients with psoriatic arthritis in a Canadian clinical practice setting: the REPArE trial. J Rheumatol 38 (2011), 1355–1362.
66. Antoni, C.E., Kavanaugh, A., van der Heijde, D., Beutler, A., Keenan, G., Zhou, B., et al. Two-year efficacy and safety of infliximab treatment in patients with active psoriatic arthritis: findings of the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT). J Rheumatol 35 (2008), 869–876.
67. Kavanaugh, A., McInnes, I.B., Mease, P., Krueger, G.G., Gladman, D., van der Heijde, D., et al. Clinical efficacy, radiographic and safety findings through 5 years of subcutaneous golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of a randomised, placebo-controlled trial (the GO-REVEAL study). Ann Rheum Dis 73 (2014), 1689–1694.
68. Mease, P., Deodhar, A., Fleischmann, R., Wollenhaupt, J., Gladman, D., Leszczyński, P., et al. Effect of certolizumab pegol over 96 weeks in patients with psoriatic arthritis with and without prior antitumour necrosis factor exposure. RMD Open, 1, 2015, e000119.
69. Kavanaugh, A., Puig, L., Gottlieb, A.B., Ritchlin, C., Li, S., Wang, Y., et al. Maintenance of clinical efficacy and radiographic benefit through 2 years of ustekinumab therapy in patients with active psoriatic arthritis: Results from the PSUMMIT 1 trial. Arthritis Care Res (Hoboken) 67:12 (2015), 1739–1749.
70. Kavanaugh, A., Mease, P.J., Reimold, A.M., Tahir, H., Rech, J., Hall, S., et al. Secukinumab for long-term treatment of psoriatic arthritis: 2-year follow-up from a phase 3, randomized, double-blind, placebo-controlled study. Arthritis Care Res (Hoboken), 2016, 10.1002/acr.23111 [Epub ahead of print].
71. European Medicines Agency, EMA/CHMP/589317/2013 Committee for Medicinal Products for Human Use (CHMP). Procedure No. EMEA/H/C/002576/0000. Remsima assessment report; 27 June 2013.
72. Gomez-Reino, J.J., Carmona, L., BIOBADASER group. Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year period. Arthritis Res Ther, 8, 2006, R29.
73. Kristensen, L.E., Gülfe, A., Saxne, T., Geborek, P., Efficacy and tolerability of anti-tumour necrosis factor therapy in psoriatic arthritis patients: results from the South Swedish Arthritis Treatment Group register. Ann Rheum Dis 67 (2008), 364–369.
74. Heiberg, M.S., Koldingsnes, W., Mikkelsen, K., Rødevand, E., Kaufmann, C., Mowinckel, P., et al. The comparative one-year performance of anti-tumor necrosis factor alpha drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: results from a longitudinal, observational, multicenter study. Arthritis Rheum 59 (2008), 234–240.
75. Saad, A.A., Ashcroft, D.M., Watson, K.D., Hyrich, K.L., Noyce, P.R., Symmons, D.P., et al. Persistence with anti-tumour necrosis factor therapies in patients with psoriatic arthritis: observational study from the British Society of Rheumatology Biologics Register. Arthritis Res Ther, 11, 2009, R52.
76. Fagerli, K.M., Lie, E., van der Heijde, D., Heiberg, M.S., Kalstad, S., Rødevand, E., et al. Switching between TNF inhibitors in psoriatic arthritis: data from the NOR-DMARD study. Ann Rheum Dis 72 (2013), 1840–1844.
77. Favalli, E.G., Selmi, C., Becciolini, A., Biggioggero, M., Ariani, A., Santilli, D., et al. Eight-year retention rate of first-line tumor necrosis factor inhibitors in spondyloarthritis: a multi-center retrospective analysis. Arthritis Care Res (Hoboken), 2016, 10.1002/acr.23090 [Epub ahead of print].
78. Fagerli, K.M., Lie, E., van der Heijde, D., Heiberg, M.S., Lexberg, A.S., Rødevand, E., et al. The role of methotrexate co-medication in TNF-inhibitor treatment in patients with psoriatic arthritis: results from 440 patients included in the NOR-DMARD study. Ann Rheum Dis 73 (2014), 132–137.
79. Iannone, F., Lopriore, S., Bucci, R., Scioscia, C., Anelli, M.G., Notarnicola, A., et al. Two-year survival rates of anti-TNF-α therapy in psoriatic arthritis (PsA) patients with either polyarticular or oligoarticular PsA. Scand J Rheumatol 44 (2015), 192–199.
80. Voulgari, P.V., Venetsanopoulou, A.I., Exarchou, S.A., Alamanos, Y., Tsifetaki, N., Drosos, A.A., Sustained clinical response and high infliximab survival in psoriatic arthritis patients: a 3-year long-term study. Semin Arthritis Rheum 37 (2008), 293–298.
81. Saougou, I., Markatseli, T.E., Papagoras, C., Voulgari, P.V., Alamanos, Y., Drosos, A.A., Sustained clinical response in psoriatic arthritis patients treated with anti-TNF agents: a 5-year open-label observational cohort study. Semin Arthritis Rheum 40 (2011), 398–406.
82. Gladman, D.D., Bombardier, C., Thorne, C., Haraoui, B., Khraishi, M., Rahman, P., et al. Effectiveness and safety of etanercept in patients with psoriatic arthritis in a Canadian clinical practice setting: the REPArE trial. J Rheumatol 38 (2011), 1355–1362.
83. Jani, M., Macphie, E., Rao, C., Moore, S., Mirjafari, H., McLoughlin, Y., et al. Effectiveness of switching between biologics in psoriatic arthritis- results of a large regional survey. Clin Med 14 (2014), 95–96.
84. Fabbroni, M., Cantarini, L., Caso, F., Costa, L., Pagano, V.A., Frediani, B., et al. Drug retention rates and treatment discontinuation among anti-TNF-α agents in psoriatic arthritis and ankylosing spondylitis in clinical practice. Mediators Inflamm, 2014, 2014, 862969.
85. Glintborg, B., Ostergaard, M., Krogh, N.S., Andersen, M.D., Tarp, U., Loft, A.G., et al. Clinical response, drug survival, and predictors thereof among 548 patients with psoriatic arthritis who switched tumor necrosis factor α inhibitor therapy: results from the Danish Nationwide DANBIO Registry. Arthritis Rheum 65 (2013), 1213–1223.
86. Rudwaleit, M., Van den Bosch, F., Kron, M., Kary, S., Kupper, H., Effectiveness and safety of adalimumab in patients with ankylosing spondylitis or psoriatic arthritis and history of anti-tumor necrosis factor therapy. Arthritis Res Ther, 12, 2010, R117.
87. Ritchlin, C., Rahman, P., Kavanaugh, A., McInnes, I.B., Puig, L., Li, S., et al. Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial. Ann Rheum Dis 73 (2014), 990–999.
88. Jaffe, G.J., Dick, A.D., Brézin, A.P., Nguyen, Q.D., Thorne, J.E., Kestelyn, P., et al. Adalimumab in Patients with Active Noninfectious Uveitis. N Engl J Med 375 (2016), 932–943.
89. Rose, S., Toloza, S., Bautista-Molano, W., Helliwell, P.S., GRAPPA Dactylitis Study Group. Comprehensive treatment of dactylitis in psoriatic arthritis. J Rheumatol 41 (2014), 2295–2300.
90. Orbai, A.M., Weitz, J., Siegel, E.L., Siebert, S., Savage, L.J., Aydin, S.Z., et al. Systematic review of treatment effectiveness and outcome measures for enthesitis in psoriatic arthritis. J Rheumatol 41 (2014), 2290–2294.
91. Cantini, F., Niccoli, L., Benucci, M., Chindamo, D., Nannini, C., Olivieri, I., et al. Switching from infliximab to once-weekly administration of 50 mg etanercept in resistant or intolerant patients with ankylosing spondylitis: results of a fifty-four-week study. Arthritis Rheum 55 (2006), 812–816.
92. Braun, J., Sieper, J., Therapy of ankylosing spondylitis and other spondyloarthritides: established medical treatment, anti-TNF-a therapy and other novel approaches. Arthritis Care Res 4 (2002), 307–321.
93. Plasencia, C., Pascual-Salcedo, D., Garcı´a-Carazo, S., Lojo, L., Nuno, L., Villalba, A., et al. The immunogenicity to the first anti-TNF therapy determines the outcome of switching to a second anti-TNF therapy in spondyloarthritis patients. Arthritis Res Ther, 15, 2013, R79.
94. Garces, S., Demengeot, J., Benito-Garcia, E., The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: a systematic review of the literature with a meta-analysis. Ann Rheum Dis 72 (2013), 1947–1955.
95. Carmona, L., Gomez-Reino, J.J., BIOBADASER Group. Survival of TNF antagonists in spondylarthritis is better than in rheumatoid arthritis. Data from the Spanish registry BIOBADASER. Arthritis Res Ther, 8, 2006, R72.
96. Rosales-Alexander, J.L., Balsalobre Aznar, J., Pérez-Vicente, S., Magro-Checa, C., Drug survival of anti-tumour necrosis factor α therapy in spondyloarthropathies: results from the Spanish emAR II Study. Rheumatology (Oxford) 54 (2015), 1459–1463.
97. Delaunay, C., Farrenq, V., Marini-Portugal, A., Cohen, J.D., Chevalier, X., Claudepierre, P., Infliximab to etanercept switch in patients with spondyloarthropathies and psoriatic arthritis: preliminary data. J Rheumatol 32 (2005), 2183–2185.
98. Gomez-Reino, J.J., Carmona, L., the BIOBADASER Group. Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four year period. Arthritis Res Ther, 8, 2006, R29.
99. Coates, L.C., Cawkwell, L.S., Ng, N.W., Bennett, A.N., Bryer, D.J., Fraser, A.D., et al. Real life experience confirms sustained response to long-term biologics and switching in ankylosing spondylitis. Rheumatology 47 (2008), 897–900.
100. Conti, F., Ceccarelli, F., Marocchi, E., Magrini, L., Spinelli, F.R., Spadaro, A., et al. Switching tumour necrosis factor alpha antagonists in patients with ankylosing spondylitis and psoriatic arthritis: an observational study over a 5-year period. Ann Rheum Dis 66 (2007), 1393–1397.
101. Spadaro, A., Lubrano, E., Marchesoni, A., D'Angelo, S., Ramonda, R., Addimanda, O., et al. Remission in ankylosing spondylitis treated with anti-TNF-α drugs: a national multicentre study. Rheumatology (Oxford) 52 (2013), 1914–1919.
102. Lie, E., van der Heijde, D., Uhlig, T., Mikkelsen, K., Rødevand, E., Koldingsnes, W., et al. Effectiveness of switching between TNF inhibitors in ankylosing spondylitis: data from the NORDMARD register. Ann Rheum Dis 70 (2011), 157–163.
103. Paccou, J., Solau-Gervais, E., Houvenagel, E., et al. Efficacy in current practice of switching between anti-tumour necrosis factor-a agents in spondyloarthropathies. Rheumatology 50 (2011), 714–720.
104. Pradeep, D.J., Keat, A.C., Gaffney, K., Brooksby, A., Leeder, J., Harris, C., Switching anti-TNF therapy in ankylosing spondylitis. Rheumatology (Oxford) 47 (2008), 1726–1727.
105. Gulyas, K., Bodnar, N., Nagy, Z., Szamosi, S., Horvath, A., Vancsa, A., et al. Real-life experience with switching TNF-α inhibitors in ankylosing spondylitis. Eur J Health Econ 15:Suppl. 1 (2014), S93–S100.
106. Baeten, D., Baraliakos, X., Braun, J., Sieper, J., Emery, P., van der Heijde, D., et al. Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial. Lancet 382 (2013), 1705–1713.
107. Baeten, D., Sieper, J., Braun, J., Baraliakos, X., Dougados, M., Emery, P., et al. Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis. N Engl J Med 373 (2015), 2534–2548.
108. Mikuls, T.R., Saag, K.G., Criswell, L.A., Merlino, L.A., Kaslow, R.A., Shelton, B.J., et al. Mortality risk associated with rheumatoid arthritis in a prospective cohort of older women: results from the Iowa Women׳s Health Study. Ann Rheum Dis 61 (2002), 994–999.
109. Atzeni, F., Sarzi-Puttini, P., Botsios, C., Carletto, A., Cipriani, P., Favalli, E.G., et al. Long-term anti-TNF therapy and the risk of serious infections in a cohort of patients with rheumatoid arthritis: comparison of adalimumab, etanercept and infliximab in the GISEA registry. Autoimmun Rev 12 (2012), 225–229.
110. Minozzi, S., Bonovas, S., Lytras, T., Pecoraro, V., González-Lorenzo, M., Bastiampillai, A.J., et al. Risk of infections using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis. Expert Opin Drug Saf 15:Suppl. 1 (2016), S11–S34.
111. Nguyen-Khoa, B.A., Goehring, E.L. Jr, Alexander, K.A., Dong, W., Napalkov, P., Jones, J.K., Risk of significant infection in rheumatoid arthritis patients switching anti-tumor necrosis factor-α drugs. Semin Arthritis Rheum 42 (2012), 119–126.
112. Johnston, S.S., Turpcu, A., Shi, N., Fowler, R., Chu, B.C., Alexander, K., Risk of infections in rheumatoid arthritis patients switching from anti-TNF agents to rituximab, abatacept, or another anti-TNF agent, a retrospective administrative claims analysis. Semin Arthritis Rheum 43 (2013), 39–47.
113. Curtis, J.R., Xie, F., Chen, L., Baddley, J.W., Beukelman, T., Saag, K.G., et al. The comparative risk of serious infections among rheumatoid arthritis patients starting or switching biological agents. Ann Rheum Dis 70 (2011), 1401–1406.
114. Tocci, G., Goletti, D., Marino, V., Matucci, A., Milano, G.M., Cantini, F., et al. Cardiovascular outcomes and tumour necrosis factor antagonists in chronic inflammatory rheumatic disease: a focus on rheumatoid arthritis. Expert Opin Drug Saf 15:Suppl. 1 (2016), S55–S61.
115. Bonovas, S., Minozzi, S., Lytras, T., González-Lorenzo, M., Pecoraro, V., Colombo, S., et al. Risk of malignancies using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis. Expert Opin Drug Saf 15:Suppl. 1 (2016), S35–S54.
116. Bluett, J., Morgan, C., Thurston, L., Plant, D., Hyrich, K.L., Morgan, A.W., et al. Impact of inadequate adherence on response to subcutaneously administered anti-tumour necrosis factor drugs: results from the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate cohort. Rheumatology (Oxford) 54 (2015), 494–499.